Insmed Sees Unusually Large Options Volume (NASDAQ:INSM)

Insmed, Inc. (NASDAQ:INSM) was the target of some unusual options trading activity on Thursday. Stock investors bought 7,706 call options on the stock. This represents an increase of approximately 121% compared to the typical volume of 3,483 call options.

Key Headlines Impacting Insmed

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: Raised outlook and strong BRINSUPRI growth: Insmed increased its 2026 revenue guidance for BRINSUPRI to $1.35 billion-$1.40 billion and for ARIKAYCE to $460 million-$470 million. BRINSUPRI generated $400.1 million in third-quarter revenue, up 29% from the second quarter. Insmed Reports Third-Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Revenue exceeded expectations: Total third-quarter revenue reached $524.4 million, up 268.4% year over year and above the roughly $499.1 million analyst consensus. ARIKAYCE revenue rose 9% year over year to $124.4 million. Insmed Reports Q3 Loss, Tops Revenue Estimates
• Positive Sentiment: Loss narrowed substantially: Insmed reported a third-quarter loss of $0.46 per share, compared with a $1.75 loss in the year-earlier period. The company also launched BRINSUPRI tablets in Japan, adding a potential international growth opportunity. Insmed Raises FY26 Revenue Outlook for BRINSUPRI and ARIKAYCE
• Neutral Sentiment: Unusually high call-option activity: Traders purchased 7,706 call options, 121% above average volume. This indicates increased bullish speculation, but options activity alone does not establish a fundamental change in valuation.
• Negative Sentiment: Quarterly EPS missed estimates: The $0.46 per-share loss was wider than the consensus estimate of a $0.39 loss, creating a counterpoint to the revenue and guidance strength. Insmed Quarterly Earnings Report
• Negative Sentiment: Analyst price-target reduction: Raymond James lowered its Insmed price target from $187 to $173, signaling more cautious valuation expectations. Raymond James Cuts Target for Insmed Stock

Insider Buying and Selling at Insmed

In related news, COO Roger Adsett sold 239,850 shares of the stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $133.27, for a total value of $31,964,809.50. Following the completion of the sale, the chief operating officer directly owned 98,744 shares of the company’s stock, valued at approximately $13,159,612.88. This represents a 70.84% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director David Brennan sold 25,000 shares of the stock in a transaction dated Wednesday, September 9th. The stock was sold at an average price of $124.00, for a total value of $3,100,000.00. Following the completion of the sale, the director directly owned 39,238 shares of the company’s stock, valued at approximately $4,865,512. This represents a 38.92% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 2.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Insmed

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Virginia Estate & Retirement Planning Advisors Inc. acquired a new stake in shares of Insmed in the 3rd quarter valued at $29,000. SBI Securities Co. Ltd. raised its stake in shares of Insmed by 69.4% during the third quarter. SBI Securities Co. Ltd. now owns 349 shares of the biopharmaceutical company’s stock worth $40,000 after buying an additional 143 shares during the last quarter. CX Institutional acquired a new stake in Insmed during the 3rd quarter worth $46,000. Whittier Trust Co. of Nevada Inc. raised its position in shares of Insmed by 86.6% during the 1st quarter. Whittier Trust Co. of Nevada Inc. now owns 444 shares of the biopharmaceutical company’s stock valued at $73,000 after acquiring an additional 206 shares during the last quarter. Finally, Harbor Investment Advisory LLC bought a new stake in Insmed in the second quarter valued at about $52,000.

Insmed Price Performance

Shares of NASDAQ:INSM traded up $14.61 during midday trading on Thursday, reaching $111.59. 11,217,795 shares of the company’s stock were exchanged, compared to its average volume of 2,982,364. The firm has a market capitalization of $24.37 billion, a PE ratio of -27.15 and a beta of 0.83. The company’s 50 day simple moving average is $113.29 and its two-hundred day simple moving average is $126.28. Insmed has a 12 month low of $90.39 and a 12 month high of $212.75. The company has a debt-to-equity ratio of 0.74, a quick ratio of 3.40 and a current ratio of 3.72.

Insmed (NASDAQ:INSM) last announced its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.07). The business had revenue of $524.43 million for the quarter, compared to the consensus estimate of $499.06 million. Insmed had a negative return on equity of 123.94% and a negative net margin of 76.94%. The firm’s revenue for the quarter was up 268.4% on a year-over-year basis. During the same quarter in the prior year, the business earned ($1.75) EPS. Equities research analysts expect that Insmed will post -1.60 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the stock. Guggenheim dropped their price target on shares of Insmed from $207.00 to $205.00 and set a “buy” rating on the stock in a research note on Friday, August 7th. Truist Financial reissued a “buy” rating and issued a $195.00 price target (up from $185.00) on shares of Insmed in a research note on Monday, August 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Insmed in a research report on Thursday, October 15th. The Goldman Sachs Group began coverage on shares of Insmed in a research report on Thursday, September 24th. They set a “buy” rating and a $188.00 target price on the stock. Finally, Morgan Stanley cut their price objective on Insmed from $218.00 to $213.00 and set an “overweight” rating on the stock in a research note on Wednesday, October 21st. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $197.26.

About Insmed

Insmed Incorporated is a global biopharmaceutical company focused on developing and commercializing therapies for serious and rare diseases. The company concentrates on conditions with significant unmet medical needs, particularly in pulmonary and infectious diseases.

Insmed’s lead commercial product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled antibacterial therapy used in the United States for adults with refractory Mycobacterium avium complex lung disease as part of a combination antibacterial regimen.